10X Genomics Inc (TXG) FinancialsTXG10X Genomics Inc

10X Genomics Inc (TXG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 74.5% of total sales, equivalent to $115.36M. Other significant revenue streams include Products and services revenue and Instruments. Understanding this composition is critical for investors evaluating how TXG navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, 10X Genomics Inc maintains a gross margin of 68.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -31.33%, while the net margin is -22.18%. These profitability ratios, combined with a Return on Equity (ROE) of -22.03%, provide a clear picture of how effectively TXG converts its operational activities into shareholder value.

In the context of the broader market, TXG competes directly with industry leaders such as CVAC and GPCR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TXG's gross margin of 68.08% stands against CVAC's 99.31% and GPCR's N/A. Such benchmarking helps identify whether 10X Genomics Inc is trading at a premium or discount relative to its financial performance.